Weight loss / obesityType 2 diabetesCardiovascular risk reductionNASH / MASH (fatty liver)Chronic kidney diseaseAlcohol use disorder
Typical dosing
250–500 mcg · 1x daily · 12-20 weeks
250–2400 mcg · 1x weekly · Ongoing (titrate up over 16-20 weeks)
FDA status
Not FDA-approved. GRAS (Generally Recognized As Safe) status granted by FDA for use as a food ingredient (2013). FDA 503A Category 2 bulk drug substance
FDA-approved (Ozempic for T2D 2017, Wegovy for weight management 2021, Rybelsus oral for T2D 2019)
WADA status
Prohibited at all times (S2 — Peptide Hormones, Growth Factors)
